How do JNJ and ABBV differ fundamentally?

Johnson & Johnson operates in both pharmaceutical drugs and medical devices (surgical equipment, orthopedics, cardiovascular). AbbVie is a pure pharmaceutical company with primary focus on immunology (Skyrizi, Rinvoq, Humira) and aesthetics (Botox, Juvederm). J&J's device business provides revenue diversification beyond drug patent cycles; AbbVie's purity creates more earnings leverage to immunology drug performance.

What metrics matter most when comparing JNJ and ABBV?

For J&J, track Darzalex and Carvykti combined revenue growth, MedTech organic growth, and the magnitude of Stelara revenue decline from biosimilar entry. For AbbVie, track Skyrizi and Rinvoq combined quarterly revenue (these must eventually offset Humira decline), Botox/aesthetics quarterly performance, and Humira US revenue vs prior year as biosimilar erosion rates settle.

Which is better for long-term investors — JNJ or ABBV?

Both are excellent healthcare income compounders. J&J's 60+ year dividend increase streak and diversified business model make it the standard 'defensive healthcare hold' for long-term investors. AbbVie's Skyrizi/Rinvoq story if successful creates a second act of growth beyond Humira that could provide better total return. Long-term healthcare investors often hold both for dividend income with different risk profiles.

Data as of: June 15, 2026

brimindinvest.com / compare / jnj-vs-abbvLIVE

JNJ

Johnson & Johnson · Healthcare

N/A

N/A this month

VERSUS

COMPARE

ABBV

AbbVie Inc. · Healthcare

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

JNJ N/A

ABBV N/A

1Y Returni

JNJ N/A

ABBV N/A

Fwd P/Ei

JNJ N/A

ABBV N/A

Target Up.i

JNJ N/A

ABBV N/A

Op. Margini

JNJ N/A

ABBV N/A

Quick take

JNJ vs ABBV Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

Johnson & Johnson and AbbVie are both large-cap pharmaceutical companies with strong dividend histories facing near-term headwinds from biosimilar competition. J&J faces Stelara biosimilar pressure but has MedTech diversification and Darzalex/Carvykti oncology upside. AbbVie faces Humira biosimilar devastation but has Skyrizi/Rinvoq immunology replacements growing rapidly and Botox as a durable aesthetics franchise. Both are income-oriented large-cap healthcare holdings with different pipeline replacement execution stories.

JNJ vs ABBV is diversified pharma-plus-medical-devices with oncology growth (Darzalex, Carvykti) offsetting Stelara biosimilar headwind (J&J) versus pure pharma immunology specialist replacing $20B Humira revenue with Skyrizi/Rinvoq while Botox provides aesthetics stability (AbbVie) — both navigating major biosimilar transitions with strong pipeline replacements.

Normalized 1Y performance

JNJ

ABBV

Not enough data to chart yet.

Recent returns

JNJ

ABBV

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

JNJ

Price target data unavailable

N/A

ABBV

Price target data unavailable

N/A

Who should consider this stock?

JNJ may suit investors who:

prefer diversified healthcare with pharmaceutical and medical device combination reducing single-drug patent cliff exposure relative to pure pharma companies
value Darzalex and Carvykti oncology growth as premium-priced products in multiple myeloma with expanding market opportunity
want healthcare blue-chip with 60+ consecutive dividend increases — one of the most reliable dividend growth stocks in the market
are comfortable with Stelara biosimilar revenue headwind, ongoing talc litigation uncertainty, and MedTech competitive intensity

ABBV may suit investors who:

prefer immunology specialist with Skyrizi/Rinvoq replacing Humira at potentially greater combined peak revenue by 2027
value AbbVie's Botox aesthetics franchise as a uniquely brand-protected premium product with limited biosimilar risk in the near term
want the highest current dividend yield among large-cap pharma — AbbVie's commitment to dividend growth is very strong
are comfortable with Humira revenue decline magnitude through 2026, Skyrizi/Rinvoq immunology competition from peers, and aesthetics segment cyclicality

Performance & AI score

Performance & AI score
Metric	JNJ	ABBV
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A
1M returni	N/A	N/A
6M returni	N/A	N/A
1Y returni	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	JNJ	ABBV
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	JNJ	ABBV
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

JNJ max drawdowniN/A

ABBV max drawdowniN/A

JNJ max wkly dropiN/A

ABBV max wkly dropiN/A

5Y risk snapshot

JNJ max drawdowniN/A

ABBV max drawdowniN/A

JNJ max wkly dropiN/A

ABBV max wkly dropiN/A

10Y risk snapshot

JNJ max drawdowniN/A

ABBV max drawdowniN/A

JNJ max wkly dropiN/A

ABBV max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	JNJ	ABBV
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

JNJ

+2.8%BUY

ABBV

+1.1%HOLD

Next 30 trading days

JNJ

+6.4%BUY

ABBV

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	JNJ	ABBV
Company	Johnson & Johnson	AbbVie Inc.
Sector	Healthcare	Healthcare
Industry	N/A	N/A
Core business	Johnson & Johnson is one of the world's largest healthcare companies, operating two segments: Innovative Medicine (pharmaceutical drugs including Stelara, Darzalex, Tremfya, Carvykti) and MedTech (surgical devices, orthopedics, cardiovascular equipment). J&J spun off its consumer health segment (Kenvue) in 2023, focusing on higher-margin pharmaceutical and medical device businesses. J&J's pharmaceutical pipeline has notable oncology (Darzalex, Carvykti CAR-T) and immunology (Tremfya) programs.	AbbVie is the world's top-selling drug by revenue via Humira (adalimumab) — an anti-inflammatory biologic that generated $20B+ at peak. Humira biosimilar competition began in the US in 2023, creating a significant revenue headwind. AbbVie has invested heavily in replacing Humira through Skyrizi (risankizumab for psoriasis and IBD) and Rinvoq (upadacitinib for rheumatoid arthritis, atopic dermatitis) — both are growing rapidly. AbbVie's Allergan acquisition added Botox, fillers, and aesthetics to its portfolio.
Investor focus	Investors track Darzalex (multiple myeloma) and Carvykti (CAR-T cell therapy) sales growth, MedTech procedure volume recovery, Innovative Medicine pipeline milestones, and Stelara biosimilar revenue headwind management.	Investors track Skyrizi and Rinvoq combined sales growth vs Humira biosimilar revenue decline, Botox (neurotoxin) and aesthetics revenue, and oncology pipeline progress (NaviNe, epkinly).

JNJ strengths

Most diversified large-cap pharma with pharmaceutical + medical device combination — device revenue is less patent-cliff dependent than drug revenue
Darzalex is one of the world's best-selling oncology drugs — still growing and expanding into earlier lines of multiple myeloma treatment
Carvykti CAR-T cell therapy represents next-generation oncology — manufacturing capacity expansion is enabling rapid revenue growth in this premium-priced treatment

ABBV strengths

Skyrizi and Rinvoq are both best-in-class immunology drugs growing 40–50% annually — AbbVie's internal forecasts project these drugs replacing and exceeding Humira's peak revenue by 2027
Botox neurotoxin is the global brand standard in aesthetics and medical neurotoxin — monopoly-like position in premium aesthetics with limited biosimilar risk
AbbVie's immunology expertise after decades of Humira development creates a durable pipeline in immune-mediated diseases where it has deep clinical and regulatory expertise

Risks to watch — JNJ

Stelara (formerly $10B+ revenue drug) faces biosimilar competition beginning 2025 — this patent cliff represents a significant revenue headwind J&J must offset with pipeline launches
Talc liability litigation (baby powder lawsuits) remains an ongoing legal overhang with potential significant settlement costs
MedTech competitive intensity from Medtronic, Abbott, and Stryker in J&J's device segments

Risks to watch — ABBV

Humira biosimilar revenue decline is dramatic and rapid — managing the transition from Humira revenue to Skyrizi/Rinvoq is a multi-year earnings story
Skyrizi and Rinvoq competition from AstraZeneca, Pfizer, and Lilly in overlapping indications could limit pricing power in immunology
Aesthetics market cyclicality — Botox/filler revenues are more consumer-discretionary than pharmaceutical revenues and can slow in economic downturns

Frequently asked questions

J&J's diversification across pharmaceutical and medical devices provides more stability across any single drug's patent cliff. AbbVie's Skyrizi/Rinvoq replacement story is compelling and the dividend yield is often higher than J&J. For diversified healthcare blue-chip quality, J&J; for higher current income with immunology pipeline replacement execution, AbbVie. Both are excellent long-term healthcare income holdings.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons